Quarterly Updates21 May 2026, 10:51 pm
Aurobindo Pharma FY26: Revenue ₹111,717.2 Mn
AI Summary
Aurobindo Pharma Ltd's board approved the standalone and consolidated audited financial results for the year ended March 31, 2026. The company reported total revenue from operations of ₹111,717.2 million and a profit after tax of ₹24,148.0 million. The board also approved the resignation of M/s. MRR & Associates as Secretarial Auditor and appointed M/s. RPR & Associates as the new Secretarial Auditors. Additionally, M/s. Ernst & Young LLP were re-appointed as Internal Auditors.
Key Highlights
- Aurobindo Pharma's FY26 revenue from operations reached ₹111,717.2 million.
- The company's profit after tax for FY26 stood at ₹24,148.0 million.
- M/s. RPR & Associates appointed as Secretarial Auditors for five years.
- M/s. Ernst & Young LLP re-appointed as Internal Auditors for June 2026 to May 2027.
- Auditors issued unmodified opinion on Standalone and Consolidated Financial Results.